Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report

Table 1 Induction chemotherapy followed by chemoradiotherapy for locally advanced sinonasal undifferentiated carcinoma

Ref.	Year	n	T Stage(T3/4)	N Stage(N0/1/2)	Induction chemotherapy (cycle, regimen)	Chemoradiotherapy(radiation dose, regimen)	ENI	MST1 (mo, range)
Musy et al[11]	2002	5	NS2	NS	3, CAV/EP	55-63 Gy, NS	-	9 (4-114)
Rischin et al[12]	2004	7	0/7	4/1/2	3, FC/FP	50-60 Gy, CBDCA/CDDP	+	21 (5-51)
Yoshida et al[16]	2008	1	0/1	0/0/1	NS, EP	72 Gy, CDDP	+	41
Mourad et al[14]	2013	3	0/3	3/0/0	2-3, CDDP/FP/TPF	3DCRT/IMRT of 60-70 Gy, CDDP3	+	27 (16-28)
Ansari et al[22]	2013	1	0/1	0/0/1	3, EAP	60 Gy, CBDCA	-	16
Gray et al[2]	2015	3	0/3	2/0/1	NS, EC/EP	PB of 70 CGE, EC/EP	+	34 (32-58)
Zielinski et al[15]	2016	1	0/1	0/1/0	6, TPF	60 Gy, CDDP	NS	17
Bhasker et al[21]	2017	5	NS	NS	2, EP/FP/TC	3DCRT of 70 Gy, CDDP	+	6 (2.4-34.2)
Sienna et al[23]	2018	1	0/1	0/0/1	3, CDDP	50 Gy, CDDP	-	17
Our cases		2	0/2	0/0/0	3, TPF	IMRT of 70 Gy, CDDP	-	44

¹MST represents the duration of survival among the patients receiving induction chemotherapy and chemoradiotherapy.

²All patients were classified as Kadish C.

³Part of patients received CDDP concomitantly with irradiation. CAV: Cyclophosphamide, doxorubicin and vincristine; CBDCA: Carboplatin; CDDP: Cisplatin; CGE: Cobalt-gray equivalents; EAP: Etoposide, doxorubicin and cisplatin; EC: Etoposide and carboplatin; ENI: Elective nodal irradiation; EP: Etoposide and cisplatin; FC: Fluorouracil and carboplatin; FP: Fluorouracil and cisplatin; IMRT: Intensity-modulated radiotherapy; MST: Median survival time; NS: Not specified; PB: Proton beam radiation; TC: Paclitaxel and carboplatin; TPF: Docetaxel, cisplatin and fluorouracil; 3DCRT: 3-dimensional conformal radiotherapy.